Certara clarifies 2025 adjusted EBITDA figure

Certara, Inc. clarified financial information related to its recently divested Regulatory and Medical Writing business that had been discussed on its second quarter 2026 earnings conference call and in the accompanying presentation.

Rhea-AI Filing Summary

Certara, Inc. clarified financial information related to its recently divested Regulatory and Medical Writing business that had been discussed on its second quarter 2026 earnings conference call and in the accompanying presentation. Management had described the business as having generated approximately $17 million of adjusted EBITDA in 2025 “excluding unallocated overhead costs,” which was incorrect.

The company states that the approximately $17 million of adjusted EBITDA for 2025 is calculated including unallocated overhead costs. On an alternative basis that excludes unallocated corporate expense that will remain with Certara, the business generated approximately $23 million of adjusted EBITDA in 2025. Certara indicates that this clarification does not affect any previously reported financial results, year-over-year comparisons, or its 2026 financial outlook.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Key Figures

2025 adjusted EBITDA including unallocated overhead: approximately $17 million 2025 adjusted EBITDA excluding unallocated corporate expense: approximately $23 million Common stock par value: $0.01 per share

3 metrics

2025 adjusted EBITDA including unallocated overhead approximately $17 million Adjusted EBITDA in 2025 for the divested Regulatory and Medical Writing business including unallocated overhead costs

2025 adjusted EBITDA excluding unallocated corporate expense approximately $23 million Adjusted EBITDA in 2025 for the Regulatory and Medical Writing business excluding unallocated corporate expense that will remain with Certara

Common stock par value $0.01 per share Par value of Certara, Inc. common stock as listed in the registration table

Key Terms

Regulation FD Disclosure, adjusted EBITDA, unallocated corporate expense, earnings conference call

4 terms

Regulation FD Disclosure regulatory

"Item 7.01 Regulation FD Disclosure."

Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.

adjusted EBITDA financial

"generated approximately $17 million of adjusted EBITDA in 2025"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

unallocated corporate expense financial

"excluding unallocated corporate expense that will remain with the Company"

earnings conference call financial

"hosted its second quarter 2026 earnings conference call"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What clarification did Certara (CERT) provide about its 2025 adjusted EBITDA?

Certara clarified that its divested Regulatory and Medical Writing business generated approximately $17 million of adjusted EBITDA in 2025 including unallocated overhead costs. Earlier, this same $17 million figure was mistakenly described as excluding unallocated overhead on the Q2 2026 earnings call and in the related presentation.

What is the 2025 adjusted EBITDA for Certara's divested unit excluding certain corporate expenses?

Certara reports that the divested Regulatory and Medical Writing business generated approximately $23 million of adjusted EBITDA in 2025 excluding unallocated corporate expense that will remain with the company. This provides an additional view of the business’s performance separate from overhead that stays with Certara.

Does Certara's clarification affect previously reported CERT financial results?

Certara states that the clarification has no impact on previously reported financial results. The change corrects how the 2025 adjusted EBITDA of the divested Regulatory and Medical Writing business was described, without altering historical financial statements or year-over-year comparisons.

Does the corrected EBITDA disclosure change Certara's 2026 financial outlook?

No. Certara explicitly notes that the clarification has no impact on its 2026 Financial Outlook. The adjustment relates only to wording around the 2025 adjusted EBITDA of the divested Regulatory and Medical Writing business, rather than to current-year guidance figures.

Which Certara business is affected by the corrected 2025 EBITDA figure?

The clarification concerns Certara’s recently divested Regulatory and Medical Writing business. The company corrected its description of that unit’s 2025 adjusted EBITDA on the Q2 2026 earnings call and updated the related earnings presentation posted on its investor relations website.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 04:20 PM Accepted by SEC EDGAR 08/07/2026 - 04:20 PM Learn about SEC filing dates

false 0001827090 0001827090 2026-08-04 2026-08-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 4, 2026

Certara, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-39799	82-2180925
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4 Radnor Corporate Center Suite 350
Radnor, Pennsylvania		19087
(Address of principal executive offices)		(Zip Code)

(415) 237-8272

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.01 per share	CERT	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company, as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

Item 7.01 Regulation FD Disclosure.

On August 4, 2026, Certara, Inc. (the “Company”) hosted its second quarter 2026 earnings conference call and posted on its website its second quarter 2026 earnings presentation. On the earnings conference call, there was a misstatement in the spoken reference to the 2025 adjusted EBITDA generated by the Company’s recently divested Regulatory and Medical Writing business, which was quoted as having “generated approximately $17 million of adjusted EBITDA in 2025 excluding unallocated overhead costs” (emphasis added), which should have been quoted as having “generated approximately $17 million of adjusted EBITDA in 2025 including unallocated overhead costs” (emphasis added).

The 2025 adjusted EBITDA generated by the Regulatory and Medical Writing business excluding unallocated corporate expense that will remain with the Company is approximately $23 million.

The second quarter 2026 earnings presentation contained the same misstatement and an updated version of the presentation has been posted to the Company’s website, available at ir.certara.com under the heading “Financials & Filings—Quarterly Results”.

The foregoing clarification has no impact on previously reported financial results, year-over-year comparisons or the Company’s 2026 Financial Outlook.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	August 7, 2026	CERTARA, INC.
		(Registrant)
		By:	/s/ Daniel D. Corcoran
			Daniel D. Corcoran
			Senior Vice President and General Counsel

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.8 KB